drugset / Trial / NCT02516904

A Single Ascending Dose Study of CD101 IV in Healthy Subjects

NCT02516904

Phase 1 Completed 32 enrolled Cidara Therapeutics Inc.
RandomizedSingle-groupQuadruple-blindTreatment

Summary

A single ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of CD101 IV

Timeline

Start
2015-07
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Rezafungin Other / unclassified Intravenous

Indications

No indication recorded.